Abacus Life, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a
pioneering alternative asset manager specializing in longevity and
actuarial technology, today announced preliminary unaudited
financial results for the second quarter ended June 30, 2024.
Preliminary Financial Results - Second
Quarter 2024
Based upon management's current expectations,
the Company anticipates Total Revenue, Net Income, and Adjusted
EBITDA, for the second quarter as follows:
|
2Q24 |
Total Revenue |
Between $28.0 and $30.0 million |
Net Income |
Between $0.0 and $1.0 million |
Adjusted EBITDA |
Between $15.0 and $17.0 million |
|
|
“We are thrilled to deliver another strong
quarter of growth and profitability as we remain well on track to
achieve all of our goals for 2024,” said Jay Jackson, Chief
Executive Officer of Abacus. “Our momentum continues to accelerate
as we execute on our key strategies to drive long-term growth.
During the quarter, we successfully completed a public offering
that generated over $90 million of net proceeds, which will be
instrumental in pursuing growth opportunities. Additionally, we
established a new national distribution relationship with AIMCOR in
which Abacus will offer its expertise and become a preferred
partner for life settlement solutions to AIMCOR and its affiliates.
Along with today’s earlier announcement of our agreement to acquire
Carlisle Management Company SCA, these achievements underscore the
strength and resilience of our business model and our commitment to
delivering value to our shareholders.”
Earnings Release and Conference
Call
Abacus Life, Inc. will release its Second
Quarter 2024 financial results before the market opens on Monday,
August 12, 2024. Management will hold a conference call to discuss
the financial results at 9:00 am Eastern Time on August 12, 2024. A
live webcast of the conference call will be available on Abacus’
investor relations website at ir.abacuslife.com. The dial-in number
for the conference call is (877) 407-9716 (toll-free) or (201)
493-6779 (international). Please dial the number 10 minutes prior
to the scheduled start time.
Preliminary Information
The unaudited financial and operational
information presented in this press release is preliminary and may
change. Abacus’ financial closing procedures with respect to the
estimated financial information provided in this press release are
not yet complete, and as a result, the Company's final results may
vary materially from the preliminary results included in this press
release. Abacus undertakes no obligation to update or supplement
the information provided in this press release until the Company
releases its financial statements for the three months ended June
30, 2024. The preliminary financial information included in this
press release reflects the Company's current estimates based on
information available as of the date of this press release and has
been prepared by Company management. This preliminary financial and
operational information should not be viewed as a substitute for
full financial statements prepared in accordance with GAAP and is
not necessarily indicative of the results to be achieved for any
future periods. This preliminary financial information could be
impacted by the effects of financial closing procedures, final
adjustments, and other developments.
Non-GAAP Financial
Information
Adjusted EBITDA, a non-GAAP measure, is defined
as net income (loss) attributable to Abacus adjusted for
depreciation expense, amortization, interest expense, income tax
and other non-cash and certain non-recurring items that in our
judgement significantly impact the period-over-period assessment of
performance and operating results that do not directly relate to
business performance within Abacus’ control. A reconciliation of
Adjusted EBITDA to Net income attributable to Abacus Life, the most
directly comparable GAAP measure, appears below.
Forward-Looking Statements
All statements in this press release (and oral
statements made regarding the subjects of this press release) other
than historical facts are forward-looking statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements rely on a number of
assumptions concerning future events and are subject to a number of
uncertainties and factors that could cause actual results to differ
materially from such statements, many of which are outside the
control of Abacus. Forward-looking information includes but is not
limited to statements regarding: Abacus’s financial and operational
outlook; Abacus’s operational and financial strategies, including
planned growth initiatives and the benefits thereof, Abacus’s
ability to successfully effect those strategies, and the expected
results therefrom. These forward-looking statements generally are
identified by the words “believe,” “project,” “estimate,” “expect,”
“intend,” “anticipate,” “goals,” “prospects,” “will,” “would,”
“will continue,” “will likely result,” and similar expressions
(including the negative versions of such words or expressions).
While Abacus believes that the assumptions
concerning future events are reasonable, it cautions that there are
inherent difficulties in predicting certain important factors that
could impact the future performance or results of its business. The
factors that could cause results to differ materially from those
indicated by such forward-looking statements include, but are not
limited to: the fact that Abacus’s loss reserves are based on
estimates and may be inadequate to cover its actual losses; the
failure to properly price Abacus’s insurance policies; the
geographic concentration of Abacus’s business; the cyclical nature
of Abacus’s industry; the impact of regulation on Abacus’s
business; the effects of competition on Abacus’s business; the
failure of Abacus’s relationships with independent agencies; the
failure to meet Abacus’s investment objectives; the inability to
raise capital on favorable terms or at all; the effects of acts of
terrorism; and the effectiveness of Abacus’s control environment,
including the identification of control deficiencies.
These forward-looking statements are also
affected by the risk factors, forward-looking statements and
challenges and uncertainties set forth in documents filed by Abacus
with the U.S. Securities and Exchange Commission from time to
time, including the Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q and subsequent periodic reports. These
filings identify and address other important risks and
uncertainties that could cause actual events and results to differ
materially from those contained in the forward-looking statements.
Abacus cautions you not to place undue reliance on the
forward-looking statements contained in this press release.
Forward-looking statements speak only as of the date they are made.
Readers are cautioned not to put undue reliance on forward-looking
statements, and Abacus assumes no obligation and, except as
required by law, does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise. Abacus does not give any assurance
that it will achieve its expectations.
About Abacus
Abacus is a leading vertically integrated
alternative asset manager and market maker, specializing in
longevity and actuarial technology. The company is democratizing
the life insurance space through three groundbreaking new channels:
ABL Tech, ABL Wealth, and ABL Longevity Growth & Income Funds.
Since 2004, Abacus has purchased life insurance policies from
consumers seeking liquidity and has actively managed those policies
over time (via trading, holding, and/or servicing). With over $5BN
in face value of policies purchased, we have helped thousands of
clients maximize the value of life insurance. Abacus Life is the
only public life settlement company, trading on the Nasdaq Exchange
under the ticker symbol ABL.
Over the past 20 years, the company has built an
institutionalized origination and portfolio management process that
is supported by a 100+ person team, long-term relationships with 78
institutional partners and 30,000 financial advisors, and the
ability to operate in 49 states. The Company complies with HIPAA
and privacy laws to maintain and protect confidentiality of
financial, health, and medical information. Abacus is also proud to
be a BBB Accredited Business with an A+ rating.
www.Abacuslife.com
Contact:Abacus Life Investor
Relationsinvestors@abacuslife.com
Abacus Life Public
Relationspress@abacuslife.com
ABACUS LIFE, INC. Adjusted EBITDA
|
Three Months Ended |
|
Three Months Ended |
|
June 30, 2024 |
|
June 30, 2023 |
|
|
|
|
|
|
|
Low |
|
High |
|
Actual |
Net income attributable to Abacus Life, Inc. |
$ |
- |
|
|
$ |
1,000,000 |
|
|
$ |
6,723,549 |
|
|
|
|
|
|
|
Net income |
|
- |
|
|
|
1,000,000 |
|
|
|
6,723,549 |
|
Depreciation and amortization expense |
|
1,650,000 |
|
|
|
1,750,000 |
|
|
|
1,098 |
|
Income tax |
|
1,400,000 |
|
|
|
1,800,000 |
|
|
|
1,184,571 |
|
Stock compensation |
|
6,100,000 |
|
|
|
6,200,000 |
|
|
|
- |
|
Due Diligence related to acquisitions |
|
1,200,000 |
|
|
|
1,400,000 |
|
|
|
Other (expense) |
|
(200,000 |
) |
|
|
(400,000 |
) |
|
|
(121,601 |
) |
Interest expense |
|
4,450,000 |
|
|
|
4,600,000 |
|
|
|
584,075 |
|
Interest income |
|
(600,000 |
) |
|
|
(650,000 |
) |
|
|
- |
|
Loss on change in fair value of debt |
|
1,000,000 |
|
|
|
1,250,000 |
|
|
|
1,445,229 |
|
Change in fair value of warrant liability |
|
550,000 |
|
|
|
650,000 |
|
|
|
- |
|
Realized & Unrealized (gain) on investments |
|
(550,000 |
) |
|
|
(600,000 |
) |
|
|
(672,936 |
) |
Adjusted EBITDA |
$ |
15,000,000 |
|
|
$ |
17,000,000 |
|
|
$ |
9,143,985 |
|
|
|
|
|
|
|
Abacus Life (NASDAQ:ABL)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
Abacus Life (NASDAQ:ABL)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024